Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

A Rare Case of Drug-induced Erectile Dysfunction with Adalimumab and Certolizumab Solved after Switch to Ustekinumab in a Crohn's Disease Patient

Author(s): Samuel Hidalgo-Rios*, Marta Alonso-Moreno, Jaime Torelló Iserte and Jose Manuel Herrera-Justiniano

Volume 18, Issue 3, 2023

Published on: 25 August, 2022

Page: [374 - 378] Pages: 5

DOI: 10.2174/1574886317666220429111341

Price: $65

conference banner
Abstract

Background: Crohn Disease (CD) is an intestinal inflammatory condition characterized by a complex pathogenesis, with elevated levels of inflammatory cytokines. Adalimumab and certolizumab are two biologic drugs inhibiting TNF-α.

Objective: We report the first case of a probable relationship, according to Naranjo causality assessment score, between two consecutive treatments with TNF-α inhibitors and induced erectile dysfunction (ED), that disappeared after switching to another biologic drug (ustekinumab).

Case Presentation: This case report describes a possible and important association of two TNF-α inhibitors (certolizumab and adalimumab) and ED in a male patient with CD, with resolution after switching to Ustekinumab (anti-interleukin 12 and 23 biologic drug). A 65 years old man experienced erectile dysfunction during treatment with an anti-TNF. The adverse effect disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Adalimumab was replaced by certolizumab and sexual disfunction symptoms appeared again, improving typically at the end of treatment periods and getting worse with each new dose.

Results: Switching to ustekinumab lead to a resolution of the erectile dysfunction.

Conclusion: We describe for the first time a sexual dysfunction possibly due to two similar anti TNF drugs and its resolution after the switch to another similar but different drug, highlighting the potential difference between biologic drugs.

Keywords: Crohn disease, sexual dysfunction, drug-related side effects, certolizumab, adalimumab, naranjo score.

« Previous Next »
[1]
Feuerstein JD, Cheifetz AS, Cheifetz AS. Crohn disease: Epidemiology, diagnosis, and management. Mayo Clin Proc 2017; 92(7): 1088-103.
[http://dx.doi.org/10.1016/j.mayocp.2017.04.010] [PMID: 28601423]
[2]
Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct 2020; 15(1): 23.
[http://dx.doi.org/10.1186/s13062-020-00280-5] [PMID: 33160400]
[3]
Cushing K, Higgins PDR. Management of Crohn disease: A review. JAMA 2021; 325(1): 69-80.
[http://dx.doi.org/10.1001/jama.2020.18936] [PMID: 33399844]
[4]
Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 2014; 39(12): 1349-62.
[http://dx.doi.org/10.1111/apt.12749] [PMID: 24749763]
[5]
Kreitenberg AJ, Ortiz EC, Arkfeld DG. Priapism after tumor necrosis factor alpha inhibitor use. Clin Rheumatol 2015; 34(4): 801-2.
[http://dx.doi.org/10.1007/s10067-014-2858-x] [PMID: 25579651]
[6]
Oh JS, Heo HM, Kim YG, Lee SG, Lee CK, Yoo B. The effect of anti-tumor necrosis factor agents on sexual dysfunction in male patients with ankylosing spondylitis: A pilot study. Int J Impot Res 2009; 21(6): 372-5.
[http://dx.doi.org/10.1038/ijir.2009.44] [PMID: 19759542]
[7]
Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers 2016; 2(1): 16003.
[http://dx.doi.org/10.1038/nrdp.2016.3] [PMID: 27188339]
[8]
Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006; 27(22): 2640-8.
[http://dx.doi.org/10.1093/eurheartj/ehl341] [PMID: 17056702]
[9]
Lue TF. Erectile dysfunction. N Engl J Med 2000; 342(24): 1802-13.
[http://dx.doi.org/10.1056/NEJM200006153422407] [PMID: 10853004]
[10]
Carneiro FS, Webb RC, Tostes RC. Emerging role for TNF-α in erectile dysfunction. J Sex Med 2010; 7(12): 3823-34.
[http://dx.doi.org/10.1111/j.1743-6109.2010.01762.x] [PMID: 20345734]
[11]
Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: A review. Andrology 2017; 5(4): 640-63.
[http://dx.doi.org/10.1111/andr.12366] [PMID: 28622464]
[12]
Dastoli S, Iannone LF, Bennardo L, et al. A rare case of drug-induced erectile dysfunction with secukinumab solved after switch to ixekizumab in a psoriatic patient: A case report. Curr Drug Saf 2020; 15(1): 69-72.
[http://dx.doi.org/10.2174/1574886314666190726155147]
[13]
Keller JJ, Lin HC. A population-based study on the association between rheumatoid arthritis and erectile dysfunction. Ann Rheum Dis 2012; 71(6): 1102-3.
[http://dx.doi.org/10.1136/annrheumdis-2011-200890] [PMID: 22219142]
[14]
Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005; 288(3): H1016-21.
[http://dx.doi.org/10.1152/ajpheart.00779.2004]
[15]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy